Paralytic peptide for use in neuromuscular therapy

ABSTRACT

The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species  Blarina  as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic.

CROSS REFERENCE TO RELATED APPLICATION

This application claims priority from U.S. application No. 60/427,682,filed Nov. 18, 2002, which is incorporated by reference herein in itsentirety.

FIELD OF THE INVENTION

The invention relates to a paralytic peptide for neuromuscular therapyand other uses requiring disruption of neuromuscular mechanisms.

BACKGROUND OF THE INVENTION

Shrews are a very ancient group of primitive mammals that resemble mostclosely the proto-mammals. They are not closely related to rodents whichevolved from different groups of mammals. According to Dufton (1992),the known venomous species of shrew are: the northern short-tailed shrew(Blarina brevicauda), the Haitian solenodon (Solenodon paradoxus), theEuropean water shrew (Neomys fodiens) and the Mediterranean shrew(Neomys anomalous). Another venomous shrew is the southern short-tailedshrew (Blarina carolinensis). It has also been suggested that the Cubansolenodon (Apotogale cubanus) and the American shrew (Sorex cinereus)could be venomous. The northern short-tailed shrew (Blarina brevicauda)and its closely related species use a paralytic venom in its saliva toparalyze insects, other invertebrates (worms, annelids etc.), nestingbirds and small mammals which it then stores, alive in its den, forfuture feeding (Martin 1981; George et al. 1986; Dufton 1992).

The shrew venom literature generally consists of seven articles from the40s and 50s and one MA thesis in 1966 [Christenbury 1966]. These aresummarized in a review [Dufton 1992]. Using a crude ammonium sulfateprecipitate of shrew saliva glands, Ellis and Krayer (1955) concludedthe active agent was probably a protein and, because of its inability todialyze, a larger protein. A major contribution of the Ellis & Krayerwork was to show activity in cats, dogs, mice, rats, guinea pigs andrabbits. Christenbury [1966] showed Ellis & Krayer's preparation stoppedoxygen consumption by mouse kidney and liver slices. Japanese patentapplication (JP 10-236963; 1998) appears to disclose an alcoholicextract of saliva glands from two shrew species (Sorex unguiculatus &Sorex shinto saevus) as a calcium channel blocker and its use as ahypotensive. The purity is low—the extract includes any compounds thatwould dissolve in 70% ethanol. There is no information about theresponsible active molecule/s in the unknown mixture of compounds.

SUMMARY OF THE INVENTION

The paralytic compound of shrew saliva remained unidentified until now.The inventors have isolated and purified a paralytic compound having thesequence shown in FIG. 1A (SEQ ID NO:1) or FIG. 1B (SEQ ID NO:2). Theinventors further show that, while a high molecular weight fraction isparalytic, the active molecule is not a large protein but, unexpectedly,a small peptide bound in a large complex of many proteins (FIG. 3, Lane1). The invention relates to a low molecular weight peptide (oroptionally a suite of related peptides), preferably, isolated andpurified from the submaxiliary saliva glands of shrews of a species suchas Blarina as a paralytic agent. All or part of the peptide or it parentpro-peptide may also be produced by recombinant DNA methods or in vitroor in vivo peptide synthesis. This novel paralytic agent is useful as aneuromuscular blocker.

As mentioned above, the active ingredient is a small peptide isolated inan unusual and unexpected combination within a large protein complex.Known mammalian saliva peptides (e.g. vassoactive intestinal polypeptide& glucagon-like peptidel [Pohl & Wank 1998]) would not be contaminantsas they are discarded with inactive, low molecular weight moleculesduring the purification protocols. The preparation of the invention isof great purity and can be extracted from an unexpected sub-cellularsource.

The present inventors have isolated and purified novel proteins from thesubmaxilary saliva glands of shrews. In accordance with one embodimentof the invention, there is provided an isolated and purified shrewsaliva peptide. In a specific embodiment, the isolated and purifiedshrew saliva peptide has the amino acid sequence shown in FIG. 1A or 1B.The invention includes methods of isolating a paralytic compound fromvenomous shrew saliva gland or shrew saliva, comprising providing thegland or saliva, isolating the paralytic compound from the gland orsaliva and optionally purifying the compound.

The present invention also provides a pharmaceutical composition or acosmetic composition that includes the isolated and purified shrewsaliva peptide, and the use of the peptide as a pharmaceuticalsubstance, neuromuscular blocker or an analgesic. The invention is yetfurther directed to the use of the isolated and purified shrew salivapeptide for treatment of migraine, myofacial and other types of pain,muscle tremors, neuromuscular diseases, excessive sweating and wrinkles.

In particular, the invention is directed to a method of preventing ortreating migraines, myofacial and other types of pain, muscle tremors,neuromuscular diseases, and excessive sweating in a mammal comprisingadministering to the mammal an isolated and purified shrew salivapeptide, for example in a pharmaceutical composition. The mammal ispreferably a human. The invention is also directed to a method ofproviding analgesia or neuromuscular blocking in a mammal comprisingadministering to a mammal a pharmaceutical composition including theisolated and purified shrew saliva peptide. The invention is furtherdirected to a method of preventing or reducing wrinkles in a mammalcomprising administering to the mammal the isolated and purified shrewsaliva peptide, for example in a cosmetic composition.

The invention is also directed to the use of the isolated and purifiedshrew saliva peptide for the preparation of antibodies, includingpolyclonal antibodies, monoclonal antibodies or functional fragmentsthereof. This invention also relates to the antibodies so produced.

The invention is yet further directed to a method of determining thepotency of a paralytic agent by administering the paralytic agent to amealworm or other insect; determining the time until onset of paralysisand/or the duration of paralysis; and wherein the time for onset ofparalysis is inversely proportional to the strength of the paralyticagent and the duration of paralysis is proportional to the strength ofthe paralytic agent.

Other features and advantages of the present invention will becomeapparent from the following detailed description. It should beunderstood, however, that the detailed description and the specificexamples while indicating preferred embodiments of the invention aregiven by way of illustration only, since various changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from the detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the invention will become more apparent fromthe following description in which reference is made to the appendeddrawings wherein:

FIG. 1. Amino acid sequences of isolated and purified shrew salivaprotein: A. (SEQ ID NO:1); B. (SEQ ID NO:2)

FIG. 2. Size exclusion chromatography of shrew submaxilary gland extractwith bioactive fractions indicated by cross-hatching.

FIG. 3. SDS-PAGE analysis of shrew submaxilary gland extract. The smallactive component exists as part of a very high molecular weight complex.

FIG. 4. First HPLC elution profile of active fraction.

FIG. 5. Second HPLC elution profile of active fraction.

FIG. 6. SDS-PAGE gel of both buccal saliva and submaxilary homogenatestained for glycoproteins.

FIG. 7. SDS-PAGE gel Coomassie stain of both buccal saliva andsubmaxilary homogenate.

FIG. 8. Capillary electrophoretogram of the isolated and purified shrewsaliva peptide in sodium borate buffer.

FIG. 9. Capillary electrophoretogram of the isolated and purified shrewsaliva peptide.

FIG. 10. Ultra-violet spectrum of the isolated and purified shrew salivapeptide.

FIG. 11. MALDI-TOF mass spectrum of the isolated and purified shrewsaliva peptide.

FIG. 12. Peptide mass mapping of tryptic peptides of the isolated andpurified shrew saliva peptide.

FIG. 13. MASCOT searching results of the MS/MS data from HPLC-ESI-Q-TOFanalysis.

FIG. 14. Mealworms immediately post-injection and with total paralysis.

DETAILED DESCRIPTION OF THE INVENTION

The invention involves isolation and purification of a peptide paralyticagent from shrew salivary gland or saliva (called “PS peptide” orsoricidin). The peptide preferably has 54 amino acids and the sequenceshown in FIG. 1A (SEQ ID NO:1) or 1B (SEQ ID NO:2). The peptide may beisolated from any shrew having paralytic activity in its saliva, such asBlarina, Neomys and Sorex shrew species. The invention also includes abioassay using the common mealworm or other insect for rapid assessmentof paralytic bioactivity. For example, the bioassay shows that paralyticsaliva administered to the mealworm can keep it paralyzed but alive forat least 7 days. The toxin is very powerful; in dose response studies a10 microlitre injection of 20% (w/v) crude gland extracts produces totalparalysis in less than 1 sec while 10% requires 10 sec for totalparalysis. The 10 microlitre sample represented about 8 micrograms oftotal soluble extracted protein (0.8 mg/mL of extract, 0.010 mL of thisinjected=0.008 mg=8 micrograms total soluble protein). Of this, thepeptide represents (as assessed from the gel stain density) about 1/10of the protein in the whole extract (far right lane of gel picture).Thus, the actual peptide injected represents about 0.8 micrograms ofmaterial or 800 nanograms. Using the bioassay and variouschromatographic methods the inventors isolated a peptide(s) with amolecular weight of about 6000 (SDS-PAGE) that shows paralytic activity.Unexpectedly, the small active component exists as part of a very highmolecular weight, multiprotein complex (FIG. 2; FIG. 3, lane 1) themolecular weight of the complex was about 600,000 daltons. It appearedin a void volume fraction from a size exclusion column (Sephadex G-200)that has a molecular weight cut-off of 600,000 daltons. Afterpurification, the complex shows a single band on the gel (FIG. 3 lane2). The peptide sequence is readily obtained by known techniques, suchas the standard sequential Edman degradation (P. Edman and G. Begg.1967. Eur. J. Biochem. 1: 80-91. H. D. Niall, 1973. Methods Enzymol. 27:942-1010.) and mass spectroscopic sequence determination.

Thus the invention includes a method of isolating and sequencing aparalytic shrew peptide by isolating the peptide as described in thisapplication and sequencing the peptide. The sequence of the isolated andpurified shrew saliva peptide is shown in FIG. 1A (SEQ ID NO:1) or FIG.1B (SEQ ID NO:2) and the invention includes variants of the sequence asdescribed herein. Two preferred methods are used to isolate the protein:i) size exclusion and ion exchange chromatography and ii) centrifugationthrough membranes with distinct molecular weight cut-offs: preferably100,000, 10,000 and 3,000 molecular weight cut-off Centricons fromAmicon other methods are also useful. The first method allows separationof the complexed active agent (very high molecular fractions) from wherea free peptide of molecular weight 6000 would normally elute from thesize exclusion chromatography column. The ion exchange chromatographicprotocols employed a anion exchanger of a sodium phosphate buffer,neutral pH. The peptide is strongly bound to the complex (increasedionic strength does not dissociate it) and preferably is exposed totreatment with sodium dodecylsulfate (SDS) or with aqueous ethanol todissociate it from the complex. Any short chain alcohol (preferably C1to C6, more preferably C2 or C3) such as isopropyl alcohol, propanol orbutanol may be used in place of ethanol. It appears that the bioactivepeptide is kept complexed in the salivary gland until it is released asan active form in the saliva. The peptide isolate is weakly reactivewith Clellands reagent indicating the presence of sulfhydryl groups andthe amino acid cysteine although it is reasonable to expect these toexist in disulfhydryl bonds. The peptide preparation also showed anabsorbance at 280 nm indicating the presence of aromatic amino acids. Inparticular, the peptide preparation showed weak absorption at 280 nm,but stronger absorption at 260 nm, indicating phenylalanine but nottyrosine and tryptophan. FIG. 14 shows mealworms immediatelypost-injection and with total paralysis.

The peptide may be modified as described below to produce variants ofthe paralytic peptide with different paralytic potencies. Some variantsthat will be developed by this process will have the potential to behaveas competitive inhibitors (e.g. antidotes) to paralysis developed inresponse to our peptide.

Peptides of the Invention

The invention provides an isolated PS peptide. The term “PS peptide” asused herein includes the peptides shown in FIG. 1A (SEQ ID NO:1) or FIG.1B (SEQ ID NO:2), homologs, analogs, mimetics, fragments or derivativesof the PS peptide.

In one embodiment, the isolated PS peptide consists of 54 amino acidresidues and has the sequence shown in FIG. 1A (SEQ ID NO:1) or FIG. 1B(SEQ ID NO:2). In another embodiment, the PS peptide comprises sequencessubstantially identity to the above-noted peptides or comprising anobvious chemical equivalents thereof. It also includes peptide sequenceplus or minus amino acids at the amino and/or carboxy terminus of theabove-noted PS peptide sequences. In yet another embodiment, theinvention includes fusion proteins, comprising the PS peptide, labeledPS peptides, analogs, homologs and variants thereof.

Within the context of the present invention, a peptide of the inventionmay include various structural forms of the primary PS peptide whichretain biological activity. For example, a peptide of the invention maybe in the form of acidic or basic salts or in neutral form. In addition,individual amino acid residues may be modified by oxidation orreduction.

In addition to the full-length amino acid sequence, the peptide of thepresent invention may also include truncations, analogs and homologs ofthe peptide and truncations thereof as described herein. Truncatedpeptides or fragments may comprise peptides of at least 5, 10, 15, 20,25, 30, 35, 40, 45 or 50 amino acids or more amino acid residues of thesequence listed above. Useful fragments also include, for example,50-54, 45-50, 45-52, 44-55, 42-54, 40-54, 35-45 or 25-35 amino acids.Useful fragments are capable of providing analgesia or neuromuscularblocking. Amino acid nos. 42-54, 40-54, 38-54 and 45-54 are examples ofuseful fragments.

The invention further provides polypeptides comprising at least onefunctional domain or at least one antigenic determinant of a PS peptide.

Analogs of the protein of the invention and/or truncations thereof asdescribed herein, may include, but are not limited to an amino acidsequence containing one or more amino acid substitutions, insertions,deletions and/or mutations. Amino acid substitutions may be of aconserved or non-conserved nature. Conserved amino acid substitutionsinvolve replacing one or more amino acids of the peptides of theinvention with amino acids of similar charge, size, and/orhydrophobicity characteristics. When only conserved substitutions aremade the resulting analog should be functionally equivalent.Non-conserved substitutions involve replacing one or more amino acids ofthe amino acid sequence with one or more amino acids which possessdissimilar charge, size, and/or hydrophobicity characteristics.

One or more amino acid insertions may be introduced into the amino acidsequences of the invention. Amino acid insertions may consist of singleamino acid residues or sequential amino acids ranging for example from 2to 15 amino acids in length. For example, amino acid insertions may beused to destroy target sequences so that the peptide is no longeractive. This procedure may be used to inhibit the activity of thepeptide of the invention.

Deletions may consist of the removal of one or more amino acids, ordiscrete portions from the amino acid sequence of the PS peptide. Thedeleted amino acids may or may not be contiguous.

Analogs of a protein of the invention may be prepared by introducingmutations in the nucleotide sequence encoding the peptide. Mutations innucleotide sequences constructed for expression of analogs of a proteinof the invention must preserve the reading frame of the codingsequences. Furthermore, the mutations will preferably not createcomplementary regions that could hybridize to produce secondary mRNAstructures such as loops or hairpins, which could adversely affecttranslation of the mRNA.

Mutations may be introduced at particular loci by synthesizingoligonucleotides containing a mutant sequence, flanked by restrictionsites enabling ligation to fragments of the native sequence. Followingligation, the resulting reconstructed sequence encodes an analog havingthe desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-specific mutagenesisprocedures may be employed to provide an altered gene having particularcodons altered according to the substitution, deletion, or insertionrequired. Deletion or truncation of a peptide of the invention may alsobe constructed by utilizing convenient restriction endonuclease sitesadjacent to the desired deletion. Subsequent to restriction, overhangsmay be filled in, and the DNA religated. Exemplary methods of making thealterations set forth above are disclosed by Sambrook et al (MolecularCloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor LaboratoryPress, 1989).

In addition, analogs of a protein of the invention can be prepared bychemical synthesis using techniques well known in the chemistry ofproteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem.Assoc. 85:2149-2154) or synthesis in homogenous solution (Houbenweyl,1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II,Thieme, Stuttgart) The peptides of the invention also include peptideshaving sequence identity to the PS peptide, mutated PS peptides and/ortruncations thereof as described herein. Such peptides have amino acidsequences that correspond to nucleic acid sequences that hybridize understringent hybridization conditions (see discussion of stringenthybridization conditions herein) with a probe used to obtain a peptideof the invention. Peptides having sequence identity will often have theregions which are characteristic of the protein.

Peptides preferably have an amino acid sequence with at least 70%, 80%,90%, 95%, 96%, 97%, 98%, 99%, preferably 80-95% or more identity withthe amino acid sequence of the PS peptide. The compound is optionallypharmaceutical grade purity (eg. for amino acids, this optionally meansin excess of 99% purity, having a uniform crystalline structure, andwhite in color). Sequence identity is most preferably assessed by theBLAST version 2.1 program advanced search (parameters as above;Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J.(1990) “Basic local alignment search tool.” J. Mol. Biol.215:403_(—)410). BLAST is a series of programs that are available onlinefrom the National Center for Biotechnology Information (NCBI) of theU.S. National Institutes of Health. The advanced blast search is set todefault parameters. (i.e. Matrix BLOSUM62; Gap existence cost 11; Perresidue gap cost 1; Lambda ratio 0.85 default).

The invention also contemplates isoforms of the peptides of theinvention. An isoform contains the same number and kinds of amino acidsas a peptide of the invention, but the isoform has a differentthree-dimensional molecular structure. The isoforms contemplated by thepresent invention are those having the same properties as a peptide ofthe invention as described herein.

The present invention also includes a protein of the inventionconjugated with a selected protein, or a selectable marker protein toproduce fusion proteins. For example, the cDNA sequence to the PSpeptide can be inserted into a vector that contains a nucleotidesequence encoding another peptide (e.g. GST-glutathione succinyltransferase). The fusion protein is expressed and recovered fromprokaryotic (e.g. bacterial or baculovirus) or eukaryotic cells. Thefusion protein can then be purified by affinity chromatography basedupon the fusion vector sequence and the PS peptide obtained by enzymaticcleavage of the fusion protein.

An alternative method of producing the protein is by using apoly-histidine tag. The cDNA sequence is designed to have apoly-histidine tag on the N-terminal end. The protein is expressed inprokaryotic or eukaryotic cells, and then easily isolated using anickel-affinity column. The polyhistidine (usually 6 histidines) adsorbsstrongly to the nickel attached to the affinity column while nothingelse binds strongly. The ‘his-tagged’ peptide is isolated by washing thecolumn with imidazole.

The proteins of the invention (including truncations, analogs, etc.) maybe prepared using recombinant DNA methods. Accordingly, nucleic acidmolecules of the present invention having a sequence that encodes apeptide of the invention are isolated using known technologies and areincorporated according to procedures known in the art into anappropriate expression vector that ensures good expression of thepeptide. The cDNA is preferably obtained by ReverseTranscriptase-Polymerase Chain Reaction (RT-PCR). The technology comesas a kit form. One isolates the messenger RNA that encodes the peptideand then uses reverse transcriptase to convert all messengers in anextract of tissue to cDNA copies. One then amplifies the cloned DNA bystandard PCR using a primer synthesized to match a segment of thepeptide. The RACE technique is useful to obtain the full mRNA transcriptsince it codes for a series of peptides that are then cleaved after abigger protein containing all of them is synthesized. Expression vectorsinclude but are not limited to cosmids, plasmids, or modified viruses(e.g., replication defective retroviruses, adenoviruses andadeno-associated viruses), so long as the vector is compatible with thehost cell used. The expression “vectors suitable for transformation of ahost cell”, means that the expression vectors contain a nucleic acidmolecule of the invention and regulatory sequences, selected on thebasis of the host cells to be used for expression, which are operativelylinked to the nucleic acid molecule. “Operatively linked” means that thenucleic acid is linked to regulatory sequences in a manner that allowsexpression of the nucleic acid.

The invention therefore includes a recombinant expression vector of theinvention containing a nucleic acid molecule of the invention, or afragment thereof, and the necessary regulatory sequences for thetranscription and translation of the inserted peptide-sequence. Suitableregulatory sequences are optionally derived from a variety of sources,including bacterial, fungal, or viral genes (For example, see theregulatory sequences described in Goeddel, Gene Expression Technology:Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990).Selection of appropriate regulatory sequences is dependent on the hostcell chosen, and may be readily accomplished by one of ordinary skill inthe art. Examples of such regulatory sequences include: atranscriptional promoter and enhancer or RNA polymerase bindingsequence, a ribosomal binding sequence, including a translationinitiation signal. Additionally, depending on the host cell chosen andthe vector employed, other sequences, such as an origin of replication,additional DNA restriction sites, enhancers, and sequences conferringinducibility of transcription may be incorporated into the expressionvector. It will also be appreciated that the necessary regulatorysequences may be supplied by the native compound and/or its flankingregions.

The invention further provides a recombinant expression vectorcomprising a DNA nucleic acid molecule of the invention cloned into theexpression vector in an antisense orientation. These vectors are usefulexperimental systems to study the peptides of the invention or itsvariants or to test antidotes. The peptides may or may not be toxic tothe host cells. They are also useful to produce large amounts of thepeptide. The vectors are particularly useful because insect-specificbiological delivery agents (e.g. viruses) will provide immobilizingagents for specifically targeted insects. Viruses targeted against aspecific insect pest are engineered to contain the gene fragment codingfor the paralytic peptide along with expression regulatory sequences.The virus would target an insect species and then, during reproducingitself, also produce the peptide. Regulatory sequences operativelylinked to the antisense nucleic acid can be chosen which direct thecontinuous expression of the antisense RNA molecule.

The recombinant expression vectors of the invention may also contain aselectable marker gene that facilitates the selection of host cellstransformed or transfected with a recombinant molecule of the invention.Examples of selectable marker genes are genes encoding a protein such asG418 and hygromycin which confer resistance to certain drugs,β-galactosidase, chloramphenicol acetyltransferase, or fireflyluciferase. Transcription of the selectable marker gene is monitored bychanges in the concentration of the selectable marker protein such asβ-galactosidase, chloramphenicol acetyltransferase, or fireflyluciferase. If the selectable marker gene encodes a protein conferringantibiotic resistance such as neomycin resistance transformant cells canbe selected with G418. Cells that have incorporated the selectablemarker gene will survive, while the other cells die. This makes itpossible to visualize and assay for expression of recombinant expressionvectors of the invention and in particular to determine the effect of amutation on expression and phenotype. It will be appreciated thatselectable markers can be introduced on a separate vector from thenucleic acid of interest.

The recombinant expression vectors may also contain genes which encode afusion moiety which provides increased expression of the recombinantprotein; increased solubility of the recombinant protein; and aid in thepurification of a target recombinant protein by acting as a ligand inaffinity purification. For example, a proteolytic cleavage site may beadded to the target recombinant protein to allow separation of therecombinant protein from the fusion moiety subsequent to purification ofthe fusion protein.

Recombinant expression vectors can be introduced into host cells toproduce a transformed host cell. These cells are useful experimentalsystems. Accordingly, the invention includes a host cell comprising arecombinant expression vector of the invention. The term “transformedhost cell” is intended to include prokaryotic and eukaryotic cells whichhave been transformed or transfected with a recombinant expressionvector of the invention. Prokaryotic cells can be transformed withnucleic acid by, for example, electroporation or calcium-chloridemediated transformation. Nucleic acid can be introduced into mammaliancells via conventional techniques such as calcium phosphate or calciumchloride co-precipitation, DEAE-dextran-mediated transfection,lipofectin, electroporation or microinjection. Suitable methods fortransforming and transfecting host cells can be found in Sambrook et al.(Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring HarborLaboratory press (1989)), and other such laboratory textbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotichost cells. For example, the peptides of the invention may be expressedin bacterial cells such as E. coli, Pseudomonas, Bacillus subtillus,insect cells (using baculovirus), yeast cells or mammalian cells. Othersuitable host cells can be found in Goeddel, Gene Expression Technology:Methods in Enzymology 185, Academic Press, San Diego, Calif. (1991).

As an example, to produce PS peptides recombinantly, for example, E.coli can be used using the T7 RNA polymerase/promoter system using twoplasmids or by labeling of plasmid-encoded proteins, or by expression byinfection with M13 Phage mGPI-2. E. coli vectors can also be used withPhage lambda regulatory sequences, by fusion protein vectors (e.g. lacZand trpE), by maltose-binding protein fusions, and byglutathione-S-transferase fusion proteins.

Alternatively, a PS peptide can be expressed in insect cells usingbaculoviral vectors, or in mammalian cells using vaccinia virus. Forexpression in mammalian cells, the cDNA sequence may be ligated toheterologous promoters and introduced into cells, such as COS cells toachieve transient or long-term expression. The stable integration of thechimeric gene construct may be maintained in mammalian cells bybiochemical selection, such as neomycin and mycophoenolic acid.

The PS DNA sequence can be altered using procedures such as restrictionenzyme digestion, fill-in with DNA polymerase, deletion by exonuclease,extension by terminal deoxynucleotide transferase, ligation of syntheticor cloned DNA sequences, site-directed sequence alteration with the useof specific oligonucleotides together with PCR. For example, one to fiveor five to ten amino acids or more may be removed or mutated.

The cDNA sequence or portions thereof, or a mini gene consisting of acDNA with an intron and its own promoter, is introduced into eukaryoticexpression vectors by conventional techniques. These vectors permit thetranscription of the cDNA in eukaryotic cells by providing regulatorysequences that initiate and enhance the transcription of the cDNA andensure its proper splicing and polyadenylation. The endogenous PS genepromoter can also be used. Different promoters within vectors havedifferent activities which alters the level of expression of the cDNA.In addition, certain promoters can also modulate function such as theglucocorticoid-responsive promoter from the mouse mammary tumor virus.

Some of the vectors listed contain selectable markers or neo bacterialgenes that permit isolation of cells by chemical selection. Stablelong-term vectors can be maintained in cells as episomal, freelyreplicating entities by using regulatory elements of viruses. Cell linescan also be produced which have integrated the vector into the genomicDNA. In this manner, the gene product is produced on a continuous basis.

Vectors are introduced into recipient cells by various methods includingcalcium phosphate, strontium phosphate, electroporation, lipofection,DEAE dextran, microinjection, or by protoplast fusion. Alternatively,the cDNA can be introduced by infection using viral vectors.

PS peptides may also be isolated from cells or tissues, includingmammalian cells or tissues, in which the peptide is normally expressed.

The protein may be purified by conventional purification methods knownto those in the art, such as chromatography methods, high performanceliquid chromatography methods or precipitation.

For example, an anti-PS antibody (as described below) may be used toisolate a PS peptide, which is then purified by standard methods.

The peptides of the invention may also be prepared by chemical synthesisusing techniques well known in the chemistry of proteins such as solidphase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-2154) orsynthesis in homogenous solution (Houbenweyl, 1987, Methods of OrganicChemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

Peptide Mimetics

The present invention also includes peptide mimetics of PS. “Peptidemimetics” are structures which serve as substitutes for peptides ininteractions between molecules (See Morgan et al (1989), Ann. ReportsMed. Chem. 24:243-252 for a review). Peptide mimetics include syntheticstructures which optionally contain amino acids and/or peptide bonds butretain the structural and functional features of a peptide, or enhanceror inhibitor of the invention. Peptide mimetics also include peptoids,oligopeptoids (Simon et al (1972) Proc. Natl. Acad, Sci USA 89:9367);and peptide libraries containing peptides of a designed lengthrepresenting all possible sequences of amino acids corresponding to apeptide of the invention.

Peptide mimetics are designed based on information obtained bysystematic replacement of L-amino acids by D-amino acids, replacement ofside chains with groups having different electronic properties, and bysystematic replacement of peptide bonds with amide bond replacements.Local conformational constraints can also be introduced to determineconformational requirements for activity of a candidate peptide mimetic.The mimetics may include isosteric amide bonds, or D-amino acids tostabilize or promote reverse turn conformations and to help stabilizethe molecule. Cyclic amino acid analogues may be used to constrain aminoacid residues to particular conformational states. The mimetics can alsoinclude mimics of inhibitor peptide secondary structures. Thesestructures can model the 3-dimensional orientation of amino acidresidues into the known secondary conformations of proteins. Peptoidsmay also be used which are oligomers of N-substituted amino acids andcan be used as motifs for the generation of chemically diverse librariesof novel molecules.

Peptides of the invention are also useful to identify lead compounds fordrug development. The structure of the peptides described herein can bereadily determined by a number of methods such as NMR and X-raycrystallography. A comparison of the structures of peptides similar insequence, but differing in the biological activities they elicit intarget molecules can provide information about the structure-activityrelationship of the target. Information obtained from the examination ofstructure-activity relationships can be used to design either modifiedpeptides, or other small molecules or lead compounds that can be testedfor predicted properties as related to the target molecule. The activityof the lead compounds is evaluated using assays similar to thosedescribed herein. Information about structure-activity relationships isobtained from co-crystallization studies. In these studies, a peptidewith a desired activity is crystallized in association with a targetmolecule, and the X-ray structure of the complex is determined. Thestructure is then optionally compared to the structure of the targetmolecule in its native state, and information from such a comparison isuseful to design compounds expected to possess.

Therapeutic and Cosmetic Methods

The paralytic agent is useful for the neuromuscular disorder marketincluding the well publicized cosmetic applications of neuromuscularblockers. (For a discussion of the use of Botox for immobilization offacial muscles and treatment of wrinkles, see: Fagien, S. 1999. PlastReconstr Surg 103: 701-713; Carruthers, J, & Carruthers, A. 1998.Dermatol Surg 24: 1244-1247). Therapeutic applications of neuromuscularblockers such as relief of migraine, myofacial and other types of pain(i.e., analgesic activity) have recently been added to existing medicaluses that include muscle tremors and neuromuscular diseases. New usesare steadily emerging including the cosmetic application of wrinklereduction and, more recently, treatment of excessive sweating (alsocalled hyperhidrosis; Blaheta, H J, Vollert, B, Zuder, D, & Rassner, G.2002. Dermatol. Surg. 28:666-671; Naumann, M & Hamm, H. 2002. Br. J.Surg. 89: 259-261).

Accordingly, in one embodiment, the present invention provides a methodof blocking neuronal activity comprising administering an effectiveamount of PS peptide such as SEQ ID NO:1 or SEQ ID NO:2 or the othercompounds described in this application to an animal in need thereof.The present invention also provides a use of an effective amount of a PSpeptide as a neuromuscular blocker. The present invention furtherprovides a use of an effective amount of a PS peptide in the manufactureof a medicament for blocking neuronal activity or providing analgesia.

Another embodiment of the invention provides a method of wound healingcomprising administering an effective amount of PS peptide to an animalin need thereof. The present invention further provides a use of the PSpeptide in wound healing, for example by providing analgesia Forexample, dressings can be embedded with the PS peptide or gelscontaining the PS peptide can be applied to dressing, to behave as along-lasting, local analgesic to wounds.

The phrase “substance that can block neuromuscular activity” as usedherein includes all the peptides of the invention described herein thatblock neuromuscular activity temporarily or permanently, including butnot limited to pain receptors (eg. a nociceptor, which is a peripheralnerve organ or mechanism for the reception and transmission of painfulor injurious stimuli).

The term “effective amount” as used herein means an amount effective andat dosages and for periods of time necessary to achieve the desiredresult (e.g., blocking neuromuscular activity).

The term “animal” as used herein includes all members of the animalkingdom and is preferably mammalian, such as human. Administering a PSpeptide or substance to an animal includes both in vivo and ex vivoadministrations.

The term “a cell” as used herein includes a single cell as well as aplurality or population of cells. Administering a PS peptide orsubstance to a cell includes both in vitro and in vivo administrations.

The phrase “block neuromuscular activity” as used herein means that thesubstance can result in a decrease in neuromuscular activity as comparedto a neuromuscular activity in the absence of the substance.

Blocking neuromuscular activity is useful for an analgesic in treatingdiseases such as migraine, tremors, neuromuscular disease, excesssweating and wrinkles. Accordingly, in a specific embodiment, thepresent invention relates to a method of treating the aforementioneddiseases comprising administering an effective amount of a PS substanceto an animal in need thereof. The present invention also provides a useof an effective amount of a substance that can block neuromuscularactivity or provide analgesia. The present invention further provides ause of an effective amount of a PS substance that can inhibitneuromuscular function to prepare a medicament to treat theaforementioned diseases.

As used herein, and as well understood in the art, “to treat” or“treatment” is an approach for obtaining beneficial or desired results,including clinical results. Beneficial or desired clinical results caninclude, but are not limited to, alleviation or amelioration of one ormore symptoms or conditions, diminishment of extent of disease,stabilized (i.e. not worsening) state of disease or disorder, preventingspread of disease or disorder, delay or slowing of disease or disorderprogression, amelioration or palliation of the disease or disorderstate, and remission (whether partial or total), whether detectable orundetectable. “Treatment” can also mean prolonging survival as comparedto expected survival if not receiving treatment.

Pharmaceutical and Cosmetic Compositions

The nucleic acids encoding the PS peptides are optionally formulatedinto a pharmaceutical composition for administration to subjects in abiologically compatible form suitable for administration in vivo. By“biologically compatible form suitable for administration in vivo” ismeant a form of the substance to be administered in which any toxiceffects are outweighed by the therapeutic effects. The substances may beadministered to living organisms including humans, and animals.

Administration of a therapeutically active amount of pharmaceuticalcompositions of the present invention is defined as an amount effective,at dosages and for periods of time necessary to achieve the desiredresult. For example, a therapeutically active amount of a substance mayvary according to factors such as the disease state, age, sex, andweight of the individual, and the ability of the substance to elicit adesired response in the individual. Dosage regimes may be adjusted toprovide the optimum therapeutic response. For example, several divideddoses may be administered daily or the dose may be proportionallyreduced as indicated by the exigencies of the therapeutic situation.

The polypeptide of the invention is preferably combined with othercomponents such as a carrier in a composition such as a pharmaceuticalcomposition or cosmetic composition. The compositions are useful whenadministered in methods of medical treatment, prevention, or diagnosisof a disease, disorder or abnormal physical state. For example, it maybe administered as a neuromuscular blocker. They are useful fortreatment of migraine, myofacial and other types of pain (analgesicfunction), muscle tremors and neuromuscular diseases, excessive sweatingand wrinkles. They are also useful for wound healing by action as alocal analgesic.

The pharmaceutical compositions can be administered to humans or animalsby a variety of methods including, but not restricted to topicaladministration, oral administration, aerosol administration,intratracheal instillation, intraperitoneal injection, injection intothe cerebrospinal fluid, intravenous injection and subcutaneousinjection. Dosages to be administered depend on patient needs, on thedesired effect and on the chosen route of administration. For example,the pharmaceutical compositions can be on a bandage, which is used forwound healing by acting as an analgesic. Nucleic acid molecules andpolypeptides may be introduced into cells using in vivo deliveryvehicles such as liposomes. They may also be introduced into these cellsusing physical techniques such as microinjection and electroporation orchemical methods such as coprecipitation or using liposomes.

The pharmaceutical compositions are prepared by known methods for thepreparation of pharmaceutically acceptable compositions which can beadministered to patients, and such that an effective quantity of thenucleic acid molecule or polypeptide is combined in a mixture with apharmaceutically acceptable vehicle. Suitable vehicles are described,for example in Remington's Pharmaceutical Sciences (Remington'sPharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA) orHandbook of Pharmaceutical Additives (compiled by Michael and Irene Ash,Gower Publishing Limited, Aldershot, England (1995)). On this basis, thecompositions include, albeit not exclusively, solutions of thesubstances in association with one or more pharmaceutically acceptablevehicles or diluents, and may be contained in buffered solutions with asuitable pH and/or be iso-osmotic with physiological fluids. In thisregard, reference can be made to U.S. Pat. No. 5,843,456.

On this basis, the pharmaceutical compositions optionally includes anactive compound or substance, such as a peptide or nucleic acidmolecule, in association with one or more pharmaceutically acceptablevehicles or diluents, and contained in buffered solutions with asuitable pH and isoosmotic with the physiological fluids. The methods ofcombining the active molecules with the vehicles or combining them withdiluents is well known to those skilled in the art. The compositionoptionally includes a targeting agent for the transport of the activecompound to specified sites within tissue.

Preparation of Antibodies

Antibodies to the peptide are useful to identify receptors and will finduse in development of diagnostic tests. Some neuromuscular conditionsresult from malfunction of the peptide target. Detecting the targetreceptor molecules and determining their density on the surface of thecell, or their location on the cell surface is useful in diagnostics.This can be done with antibody treatment after peptide administrationand then secondary detection of the antibody/peptide complexes as in thegeneral ELISA protocol. Any method of labeling the peptide that wouldreport on receptor density/location would be useful (e.g. radioactivelylabelled peptide or fluorescently tagged peptide). Once the peptide andits receptor are characterized as to how the effect is solicited, the PSpeptide or variants are used to test how the target works in othertissues or animals or people. A variant or damaged receptor/target tothe PS peptide or variant would not act in a manner that is identical tothe characterized ‘normal’ target. The invention includes an isolatedantibody immunoreactive with a polypeptide of the invention. Antibodiesare preferably generated against epitopes of the sequence. The antibodymay be labeled with a detectable marker or unlabeled. The antibody ispreferably a monoclonal antibody or a polyclonal antibody. Suchantibodies are employed to screen organisms. The antibodies are alsovaluable for immuno-purification of polypeptides from crude extracts.For example, one may contact a biological sample with the antibody underconditions allowing the formation of an immunological complex betweenthe antibody and a polypeptide recognized by the antibody and detectingthe presence or absence of the immunological complex whereby thepresence of the peptide of the invention or a similar peptide isdetected in the sample. The invention also includes compositionspreferably including the antibody, a medium suitable for the formationof an immunological complex between the antibody and a polypeptiderecognized by the antibody and a reagent capable of detecting theimmunolgical complex to ascertain the presence of the peptide of theinvention or a similar polypeptide.

To recognize the peptide of the invention, one may generate antibodiesagainst a range of unique epitopes throughout the molecule.

Monoclonal and polyclonal antibodies are prepared according to thedescription in this application and techniques known in the art. Forexamples of methods of the preparation and uses of monoclonalantibodies, see U.S. Pat. Nos. 5,688,681, 5,688,657, 5,683,693,5,667,781, 5,665,356, 5,591,628, 5,510,241, 5,503,987, 5,501,988,5,500,345 and 5,496,705 that are incorporated by reference in theirentirety. Examples of the preparation and uses of polyclonal antibodiesare disclosed in U.S. Pat. Nos. 5,512,282, 4,828,985, 5,225,331 and5,124,147 which are incorporated by reference in their entirety.

The term “antibody” as used herein to includes fragments thereof whichalso specifically react with a PS peptide or fragments thereof.Antibodies can be fragmented using conventional techniques and thefragments screened for utility in the same manner as described above.For example, F(ab′)2 fragments can be generated by treating antibodywith pepsin. The resulting F(ab′)2 fragment can be treated to reducedisulfide bridges to produce Fab′ fragments.

Chimeric antibody derivatives, i.e., antibody molecules that combine anon-human animal variable region and a human constant region are alsocontemplated within the scope of the invention. Chimeric antibodymolecules include, for example, the antigen binding domain from anantibody of a mouse, rat, or other species, with human constant regions.Conventional methods are useful to make chimeric antibodies containingthe immunoglobulin variable region which recognizes the PS peptideantigens of the invention (See, for example, Morrison et al., Proc.Natl. Acad. Sci. U.S.A. 81,6851 (1985); Takeda et al., Nature 314, 452(1985), Cabilly et al., U.S. Pat. No. 4,816,567; Boss et al., U.S. Pat.No. 4,816,397; Tanaguchi et al., European Patent Publication EP171496;European Patent Publication 0173494, United Kingdom patent GB 2177096B).It is expected that chimeric antibodies would be less immunogenic in ahuman subject than the corresponding non-chimeric antibody.

Monoclonal or chimeric antibodies specifically reactive with a proteinof the invention as described herein can be further humanized byproducing human constant region chimeras, in which parts of the variableregions, particularly the conserved framework regions of theantigen-binding domain, are of human origin and only the hypervariableregions are of non-human origin. Such immunoglobulin molecules are madeby techniques known in the art, (e.g., Teng et al., Proc. Natl. Acad.Sci. U.S.A., 80, 7308-7312 (1983); Kozbor et al., Immunology Today, 4,7279 (1983); Olsson et al., Meth. Enzymol., 92, 3-16 (1982)), and PCTPublication WO92/06193 or EP 0239400). Humanized antibodies can also becommercially produced (Scotgen Limited, 2 Holly Road, Twickenham,Middlesex, Great Britain.)

Specific antibodies, or antibody fragments, such as, but not limited to,single-chain Fv monoclonal antibodies reactive against the peptides ofthe invention may also be generated by screening expression librariesencoding immunoglobulin genes, or portions thereof, expressed inbacteria with peptides produced from the nucleic acid molecules of PSpeptides. For example, complete Fab fragments, VH regions and FV regionscan be expressed in bacteria using phage expression libraries (See forexample Ward et al., Nature 341, 544-546: (1989); Huse et al., Science246, 1275-1281 (1989); and McCafferty et al. Nature 348, 552-554(1990)). Alternatively, a SCID-hu mouse, for example the model developedby Genpharm, can be used to produce antibodies or fragments thereof.

The invention also includes methods of using the antibodies, such as indetection of receptors that bind to the peptide of the invention. Forexample, the invention includes a method for detecting the presence of apeptide of the invention by: a) contacting a sample containing one ormore peptides with an antibody of the invention under conditionssuitable for the binding of the antibody to peptides with which it isspecifically reactive; b) separating unbound peptides from the antibody;and c) detecting antibody which remains bound to one or more of thepeptides in the sample.

Research Tool

The peptide and its derivatives are useful in research protocols toexplore the neuromuscular junction and ion channels. The ability toselectively alter certain ion channels or classes of ion channelsprovides another tool with which to perturb the neuromuscular junctionin a predictable manner. This identifies the role of susceptible peptidetargets in neuromuscular functions and processes.

EXAMPLES

The following examples are illustrative embodiments and do not limit thescope of the invention.

Example 1

Isolation and Purification of the Shrew Saliva Peptide from theSubmaxilary Saliva Glands of the Shrew (Blarina brevicauda)

Tissue Processing

The left and right submaxilary glands (ranging between 100 and 200 mgtotal weight) are dissected and placed into liquid nitrogen to flashfreeze them. The tissue is crushed and powdered under liquid nitrogen.The tissue powder is quickly transferred to weighed receptacle and theweight of the transferred tissue powder is determined. The tissue isthen homogenized in 50 mM potassium phosphate buffer, pH 7.0 to providea 20% weight-to-volume (2 g/100 mL) homogenate. The homogenate iscentrifuged at 12,000×g at 4° C. for 15 minutes to pellet the celldebris. The supernatant is removed.

If the glands are not to be used immediately they are flash frozen inliquid nitrogen and stored at −80° C. or lower until processing.

Isolation of the Peptide

The methods to isolate and purify the shrew saliva protein include: i)size exclusion and ion exchange chromatography (see FIGS. 2 and 3) andii) centrifugation with distinct molecular weight cut-offs: preferably100,000, 10,000 and 3,000 molecular weight cut-off Centricons fromAmicon. The first method allows separation of the complexed active agent(very high molecular fractions) from where a free peptide of molecularweight 6000 would normally elute from the size exclusion chromatographycolumn. The ion exchange chromatographic protocols employed a anionexchanger of a sodium phosphate buffer, neutral pH. The peptide isstrongly bound to the complex (increased ionic strength does notdissociate it) and preferably is exposed to treatment with sodiumdodecylsulfate (SDS) or with aqueous ethanol to dissociate it from thecomplex. Any short chain alcohol (preferably C1 to C6, more preferablyC2 or C3) such as isopropyl alcohol, propanol or butanol may be used inplace of ethanol. Warming the crude extract at 40° C. for 20 minutesincreases the amount of isolatable peptide. It appears that thebioactive peptide is kept complexed in the salivary gland until it isreleased as an active form in the saliva. The peptide isolate is weaklyreactive with Clellands reagent indicating the presence of sulfhydrylgroups and the amino acid cysteine although it is reasonable to expectthese to exist in disulfhydryl bonds. The peptide preparation alsoshowed a weak absorbance at 280 nm and a strong absorbance at 260 nmindicating the presence of phenylalanine, but not tryptophan andtyrosine.

The size exclusion method can also include a precipitation step of thesoluble proteins with cold acetone (−20° C. or −80° C.; 10:1 v/vacetone: homogenate), which also precipitates the larger molecularweight proteins. This acetone precipitation step can be done before orafter size-fractionation. The acetone precipitate is air dried rapidlyand is active for long period of time (Ellis S & Krayer O (1955) J PharmExper Therapeutics 114: 127-137). The precipitate (˜50 mg) is dissolvedin about 1 mL of 25 mM potassium phosphate buffer and isolated by HPLCimmediately or first incubated at 40° C. before HPLC isolation.

High Pressure Liquid Chromatographic Isolation.

A way to isolate the peptide once the acetone precipitate isre-dissolved is reversed phase HPLC. A Phenomenex Jupiter C-18 column,250×4.6 mm, 5 u at 20-25° C. and a gradient elution from 10% (v/v)acetonitrile: 90% (v.v) water to 60% acetonitrile: 40% water are usedover 30 minutes and a flow rate of 1.0 mL/min. All solvents contain 0.1%(v/v) trifluoroacetic acid (TFA). This provide the elution profile shownin FIG. 4.

The active fraction of this first HPLC set is that peak eluting at about14.7 minutes. This peak is collected (See FIG. 4, bar on ‘time axis’).This material is lyophylized overnight to remove solvents and TFA.

The residue containing the main peptide of interest and 2 to 3 minorother proteins is dissolved in a minimum volume of 25 mM potassiumphosphate buffer. The solubilized peptide is purified under another HPLCprotocol. A Phenomenex Jupiter C-18 column, 250×4.6 mm, 5 u at 20-25° C.and a gradient elution from 10% (v/v) acetonitrile: 90% (v.v) water to60% acetonitrile: 40% water is used over 40 minutes and a flow rate of2.3 mL/min. All solvents contain 0.1% (v/v) trifluoroacetic acid (TFA).This provides the elution profile shown in (See Fig HPLC 02) withpeptide eluting at 13.76 min: the collected eluant shown by the solidbar on the ‘time axis’ is pure peptide. This material is lyophylizedremoving the solvents and the TFA. This material is pure peptide by HPLC(FIG. 5), by SDS-PAGE (FIGS. 6 and 7) and by CE (FIGS. 8 and 9).

Capillary Electrophoresis

Purified shrew saliva peptide (dissolved in 25 mM potassium phosphatebuffer, pH 7.0) was subjected to capillary electrophoresis using BeckmanCoulter P/ACE Capillary Electrophoresis System in a 60 cm fused silicacolumn ((75 um internal diameter, 375 um outer diameter) with sodiumborate buffer (1 Molar, run buffer) thermostated to 25° C. The voltageregime was a 0.17 minute ramp to 30,000 volts for 20 minutes at normalpolarity. The injection pressure was 0.5 pounds per square inch for 10.0seconds providing a sample volume of approximately 5 nL (nanolitres)).

FIG. 8 shows the electrophoretogram of the purified peptide in bufferand had an elution time of 2.67 minutes. FIG. 9 shows an identicalelectrophoretic run of the 25 mM potassium phosphate buffer. This peakshowed an identical uv-spectrum as that obtained with a standardspectrophotometer (see below).

Electronic Spectrum

Purified peptide was dissolved in 50 mM potassium phosphate, pH 7.0 andits ultra-violet spectrum measured (FIG. 10). The spectrum showed noabsorbtion in the 280 nm range and thus indicated that the amino acidstryptophan and tyrosine were not present in the peptide. The shouldercentred about 260 nm indicated the presence of the amino acidphenylalanine while the low absorbtion indicated only a small amount ofthe amino acid present in the peptide. Subsequent amino acid sequencingof the peptide was consistent with this as there was no tryptophan ortyrosine and only one phenylalanine residue detected.

Post-Translational Modification

Many salivary proteins are modified post-translationally by glycationbut the isolated and purified shrew saliva peptide is not a glycoproteinproduced by such a process. Shrew saliva peptide does not havecarbohydrates attached covalently to its structure.

SDS-Page

FIG. 6 shows an SDS-PAGE (15% acrylamide) gel of both buccal saliva(mouth wash) and sub-maxilary homogenate along with internal standardsof a non-glycosylated and a glycosylated protein. FIG. 7 shows a proteinstain (Coomassie) after the glycostaining was complete and is the samegel restained with Coomassie. Shrew saliva peptide appears at as themost mobile of the proteinaceous components (lowest stained, diffuseband) and did not react positively to the glycostain as did otherproteins in these biological fluids at larger molecular weight.

Example 2

Amino Acid Sequence

The purified peptide was subjected to N-terminal sequencing using theEdman sequential degradation (FIG. 1B). Mass spectroscopy/massspectroscopy (ms/ms) was used to obtain C-terminal amino acids (FIG.1A). Both sequences are useful peptides.

Molecular Ion of the Purified Peptide

The molecular mass of isolated and purified shrew saliva peptide (BrukerReflex III, MALDI-TOF, Linear mode, HCCA matrix, two layer method)provided a molecular cation (MH+) of 5805.8 Daltons and thus a molecularmass (M) of 5804.8 Daltons. (See FIG. 11)

Tryptic Digest Peptide Mass Map

The tryptic digest followed by peptide mass mapping by MALDI-TOFprovided the mass spectrogram presented in FIG. 12. This digestion massmap is absolutely distinctive of isolated and purified shrew salivapeptide. There were no matches of this mass map in and public databaseusing the MASCOT searching (FIG. 13) (Perkins et al. 1999.Electrophoresis, 20(18) 3551-3567).

Theoretical Isoelectric Points and Mass

The theoretical isoelectric point and mass of the isolated and purifiedshrew saliva protein can be calculated. The theoretical isoelectricpoint is 4.60. Its theoretical mass is 5754.51 Da with a reduction of 6mass units because of disulfide bond formation it would be 5748.5 Da.The mass shortfall from the mass spectrometry determined molecular ionis (5804.8-5748.5) 56.3 Da, and may represent 3 integral water molecules(3×18=54). If the histidine residue is protonated this would provideanother mass unit giving a mass discrepancy of 1 mass unit.

Example 3

Bioassay

The invention includes a bioassay that shows that paralytic salivaadministered to the mealworm can keep it alive for at least 7 days. FIG.14 shows mealworms immediately postinjection and with total paralysis.Other insects are also useful in the bioassay.

Example 4

Toxicity

Table 1 shows the toxicity of general crude extract (10 microliters per100 mg worm mass). Table 2 shows the toxicity of the preparation duringpurification procedure (5 microliters injection per 100 milligram ofworm).

While the present invention has been described with reference to whatare presently considered to be the preferred examples, it is to beunderstood that the invention is not limited to the disclosed examples.To the contrary, the invention is intended to cover variousmodifications and equivalent arrangements included within the spirit andscope of the appended claims.

All publications, patents and patent applications are hereinincorporated by reference in their entirety to the same extent as ifeach individual publication, patent or patent application wasspecifically and individually indicated to be incorporated by referencein its entirety.

Toxicity Studies

TABLE 1 A. General Crude extract toxicity (10 microliters per 100 mgworm mass) # # Homogenate injected paralyzed Average time concentration*worms worms to paralysis Comment 20% 5 5 <1 second Instant paralysis 10%6 6 10 seconds  5% 9 6 7 sec not paralyzed extremely laboured movement 1% 5 2 53 sec laboured movement 20% 5 0 not applicable no symptoms(boiled for 5 min) *equivalent to 2 gm tissue homogenized in 100 mLbuffer

TABLE 2 B. Toxicity of preparation during purification procedure (5microliters injection per 100 milligram of worm) Average # # time toAmount injected paralyzed first noted protein in Sample Injected wormsworms effect injection 20% 5 5 <1 sec 65 ug Acetone ppt 5 4 <3 sec 55 ugof high molec. wt. Warmed supernat. 5 5 ~5 sec 45 ug Purified peptide 65 10 sec 0.8 ug  Saline 5 0 not applicable  0 ug

REFERENCES

-   Christenbury P A (1966) MA Thesis. A study of the ecology of Blarina    brevicauda in North Carolina and of the effect of shrew toxin on the    liver and kidneys of mice. Wake Forest College, Winston-Salem, N.C.,    U.S.A.-   Daisuke K & Kaoru Y (1997) Sagami Chemical Research Center, Japan    Patent Office Publication Number 10-236963 (Date of publication of    application: 08.09.1998)-   Dufton M (1982) Pharmac. Ther. 53: 199-215-   Ellis S & Krayer O (1955) J Pharm Exper Therapeutics 114: 127-137-   Eng J (1993) USPTO Application No. 066480-   George S et al. (1986) Am. Soc. Mammal. 261: 1-9-   Martin I (1981) J. Mamm. 62: 189-192-   Pohl M & Wank S A (1998) J Biol Chem 273: 9778-9784

1. A method of providing analgesia or neuromuscular blocking in a mammalan effective amount of in need thereof comprising administering to themammal a composition comprising an isolated peptide comprising afragment of at least 10 amino acids of the amino acid sequenceDCSQDCAACS ILARPAELNT ETCILECEGK LSSNDTEGGL CKEFLHPSKV DLPR (SEQ IDNO:2), wherein both the peptide and the fragment have paralytic activityand the peptide is purified at least 90%.
 2. The method of claim 1,wherein the analgesia is analgesia of a wound.
 3. The method of claim 1,wherein the peptide is a synthetic peptide.
 4. The method of claim 1,wherein the mammal suffers from migraine, myofacial and other types ofpain, muscle tremors, neuromuscular diseases, or excessive sweating. 5.The method of claim 1, wherein the peptide is purified at least 95%. 6.The method of claim 5, wherein the peptide is purified at least 99%. 7.The method of claim 1, wherein the peptide comprises a fragment of10-15, 15-20, 20-24, 25-35, 35-45 or 45-54 amino acids of the peptide ofSEQ ID NO:2.
 8. The method of claim 1, wherein the peptide comprises thesequence DCSQDCAACS ILARPAELNT ETCILECEGK LSSNDTEGGL CKEFLHPSKV DLPR(SEQ ID NO:2), wherein the peptide has paralytic activity.
 9. The methodof claim 1, wherein the mammal is a human.